---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-017292"
form_type: "8-K"
ticker: "TGTX"
cik: "0001001316"
company_name: "TG THERAPEUTICS, INC."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T22:00:28.973697+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# TG Therapeutics reports Q3 net loss of $35.8M; ublituximab PDUFA set for Dec 28, 2022

## Summary
- Net loss of $35.8M for Q3 2022 vs $85.6M in Q3 2021; nine-month net loss of $145.3M.
- Cash, equivalents and securities totaled $197.7M as of Sept 30, 2022; funding expected into 2024.
- R&D expense fell to $20.8M from $52.0M; SG&A decreased to $14.3M from $34.9M YoY.
- Ublituximab BLA for relapsing MS has PDUFA goal date of December 28, 2022; commercial prep ongoing.
- Company plans to launch ublituximab early 2023 if FDA approves.

## SEC filing metadata
- accession: 0001558370-22-017292
- form_type: 8-K
- ticker: TGTX
- cik: 0001001316
- company_name: TG THERAPEUTICS, INC.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001316/000155837022017292/0001558370-22-017292-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001316/000155837022017292/tgtx-20221110x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-017292
- JSON: https://secwatch.observer/filing/0001558370-22-017292.json
- Plain text: https://secwatch.observer/filing/0001558370-22-017292.txt

## Key facts
- Earnings Releases
  TG THERAPEUTICS, INC. reported three months ended September 30, 2022 results: net income $35.8 million.
  - Period: three months ended September 30, 2022
  - Net income: $35.8 million
  - Result: reported results
  source text: Net loss was $35.8 million and $145.3 million for the three and nine months ended September 30, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1001316/000155837022017292/0001558370-22-017292-index.htm
- Earnings Releases
  TG THERAPEUTICS, INC. reported nine months ended September 30, 2022 results: net income $145.3 million.
  - Period: nine months ended September 30, 2022
  - Net income: $145.3 million
  - Result: reported results
  source text: Net loss was $35.8 million and $145.3 million for the three and nine months ended September 30, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1001316/000155837022017292/0001558370-22-017292-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.